151 related articles for article (PubMed ID: 21547571)
1. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.
Binder D; Hübner RH; Temmesfeld-Wollbrück B; Schlattmann P
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1575-83. PubMed ID: 21547571
[TBL] [Abstract][Full Text] [Related]
2. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Kouroussis C; Mavroudis D; Kakolyris S; Voloudaki A; Kalbakis K; Souglakos J; Agelaki S; Malas K; Bozionelou V; Georgoulias V
Lung Cancer; 2004 Jun; 44(3):363-8. PubMed ID: 15140550
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
5. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma.
Dunsford ML; Mead GM; Bateman AC; Cook T; Tung K
Ann Oncol; 1999 Aug; 10(8):943-7. PubMed ID: 10509156
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Esteban E; Villanueva N; Muñiz I; Fernández Y; Fra J; Luque M; Jiménez P; Llorente B; Capelan M; Vieitez JM; Estrada E; Buesa JM; Jiménez-Lacave A
Invest New Drugs; 2008 Feb; 26(1):67-74. PubMed ID: 17805486
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Cho M; Wang-Gillam A; Myerson R; Gao F; Strasberg S; Picus J; Sorscher S; Fournier C; Nagaraj G; Parikh P; Suresh R; Linehan D; Tan BR
HPB (Oxford); 2015 Jul; 17(7):587-93. PubMed ID: 25800066
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.
Park SH; Hong J; Kim YS; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Park J; Cho EK; Shin DB; Lee JH
Lung Cancer; 2008 Oct; 62(1):72-7. PubMed ID: 18342982
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Georgoulias VA
Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):18-24. PubMed ID: 11252884
[TBL] [Abstract][Full Text] [Related]
13. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
Lopez M
Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
[TBL] [Abstract][Full Text] [Related]
14. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Jacobs AD; Otero H; Picozzi VJ; Aboulafia DM
Cancer Invest; 2004; 22(4):505-14. PubMed ID: 15565807
[TBL] [Abstract][Full Text] [Related]
17. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Lee MY; Jung KS; Kim HS; Lee JY; Lim SH; Kim M; Jung HA; Kim SM; Sun JM; Ahn MJ; Lee J; Park SH; Yi SY; Hwang IG; Lee SC; Ahn HK; Lim DH; Lee SI; Park KW
World J Gastroenterol; 2015 Apr; 21(14):4268-74. PubMed ID: 25892878
[TBL] [Abstract][Full Text] [Related]
18. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
